Global RNA Therapeutics and Vaccines Market Insights, Forecast to 2029

TABLE OF CONTENTS

1 Study Coverage

• 1.1 RNA Therapeutics and Vaccines Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global RNA Therapeutics and Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  • 1.2.2 mRNA (messenger RNA) Therapeutics
  • 1.2.3 siRNA (small interfering RNA) Therapeutics
  • 1.2.4 Antisense Oligonucleotide Therapeutics
• 1.3 Market by Application
  • 1.3.1 Global RNA Therapeutics and Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  • 1.3.2 Hospitals
  • 1.3.3 Research Institutions
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global RNA Therapeutics and Vaccines Sales Estimates and Forecasts 2018-2029
• 2.2 Global RNA Therapeutics and Vaccines Revenue by Region
  • 2.2.1 Global RNA Therapeutics and Vaccines Revenue by Region: 2018 VS 2022 VS 2029
  • 2.2.2 Global RNA Therapeutics and Vaccines Revenue by Region (2018-2023)
  • 2.2.3 Global RNA Therapeutics and Vaccines Revenue by Region (2024-2029)
  • 2.2.4 Global RNA Therapeutics and Vaccines Revenue Market Share by Region (2018-2029)
• 2.3 Global RNA Therapeutics and Vaccines Sales Estimates and Forecasts 2018-2029
• 2.4 Global RNA Therapeutics and Vaccines Sales by Region
  • 2.4.1 Global RNA Therapeutics and Vaccines Sales by Region: 2018 VS 2022 VS 2029
  • 2.4.2 Global RNA Therapeutics and Vaccines Sales by Region (2018-2023)
  • 2.4.3 Global RNA Therapeutics and Vaccines Sales by Region (2024-2029)
  • 2.4.4 Global RNA Therapeutics and Vaccines Sales Market Share by Region (2018-2029)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

• 3.1 Global RNA Therapeutics and Vaccines Sales by Manufacturers
  • 3.1.1 Global RNA Therapeutics and Vaccines Sales by Manufacturers (2018-2023)
  • 3.1.2 Global RNA Therapeutics and Vaccines Sales Market Share by Manufacturers (2018-2023)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of RNA Therapeutics and Vaccines in 2022
• 3.2 Global RNA Therapeutics and Vaccines Revenue by Manufacturers
  • 3.2.1 Global RNA Therapeutics and Vaccines Revenue by Manufacturers (2018-2023)
  • 3.2.2 Global RNA Therapeutics and Vaccines Revenue Market Share by Manufacturers (2018-2023)
  • 3.2.3 Global Top 10 and Top 5 Companies by RNA Therapeutics and Vaccines Revenue in 2022
• 3.3 Global Key Players of RNA Therapeutics and Vaccines, Industry Ranking, 2021 VS 2022 VS 2023
• 3.4 Global RNA Therapeutics and Vaccines Sales Price by Manufacturers
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global RNA Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of RNA Therapeutics and Vaccines, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of RNA Therapeutics and Vaccines, Product Offered and Application
• 3.8 Global Key Manufacturers of RNA Therapeutics and Vaccines, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global RNA Therapeutics and Vaccines Sales by Type
  • 4.1.1 Global RNA Therapeutics and Vaccines Historical Sales by Type (2018-2023)
  • 4.1.2 Global RNA Therapeutics and Vaccines Forecasted Sales by Type (2024-2029)
  • 4.1.3 Global RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• 4.2 Global RNA Therapeutics and Vaccines Revenue by Type
  • 4.2.1 Global RNA Therapeutics and Vaccines Historical Revenue by Type (2018-2023)
  • 4.2.2 Global RNA Therapeutics and Vaccines Forecasted Revenue by Type (2024-2029)
  • 4.2.3 Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• 4.3 Global RNA Therapeutics and Vaccines Price by Type
  • 4.3.1 Global RNA Therapeutics and Vaccines Price by Type (2018-2023)
  • 4.3.2 Global RNA Therapeutics and Vaccines Price Forecast by Type (2024-2029)

5 Market Size by Application

• 5.1 Global RNA Therapeutics and Vaccines Sales by Application
  • 5.1.1 Global RNA Therapeutics and Vaccines Historical Sales by Application (2018-2023)
  • 5.1.2 Global RNA Therapeutics and Vaccines Forecasted Sales by Application (2024-2029)
  • 5.1.3 Global RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• 5.2 Global RNA Therapeutics and Vaccines Revenue by Application
  • 5.2.1 Global RNA Therapeutics and Vaccines Historical Revenue by Application (2018-2023)
  • 5.2.2 Global RNA Therapeutics and Vaccines Forecasted Revenue by Application (2024-2029)
  • 5.2.3 Global RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• 5.3 Global RNA Therapeutics and Vaccines Price by Application
  • 5.3.1 Global RNA Therapeutics and Vaccines Price by Application (2018-2023)
  • 5.3.2 Global RNA Therapeutics and Vaccines Price Forecast by Application (2024-2029)

6 US & Canada

• 6.1 US & Canada RNA Therapeutics and Vaccines Market Size by Type
  • 6.1.1 US & Canada RNA Therapeutics and Vaccines Sales by Type (2018-2029)
  • 6.1.2 US & Canada RNA Therapeutics and Vaccines Revenue by Type (2018-2029)
• 6.2 US & Canada RNA Therapeutics and Vaccines Market Size by Application
  • 6.2.1 US & Canada RNA Therapeutics and Vaccines Sales by Application (2018-2029)
  • 6.2.2 US & Canada RNA Therapeutics and Vaccines Revenue by Application (2018-2029)
• 6.3 US & Canada RNA Therapeutics and Vaccines Market Size by Country
  • 6.3.1 US & Canada RNA Therapeutics and Vaccines Revenue by Country: 2018 VS 2022 VS 2029
  • 6.3.2 US & Canada RNA Therapeutics and Vaccines Sales by Country (2018-2029)
  • 6.3.3 US & Canada RNA Therapeutics and Vaccines Revenue by Country (2018-2029)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe RNA Therapeutics and Vaccines Market Size by Type
  • 7.1.1 Europe RNA Therapeutics and Vaccines Sales by Type (2018-2029)
  • 7.1.2 Europe RNA Therapeutics and Vaccines Revenue by Type (2018-2029)
• 7.2 Europe RNA Therapeutics and Vaccines Market Size by Application
  • 7.2.1 Europe RNA Therapeutics and Vaccines Sales by Application (2018-2029)
  • 7.2.2 Europe RNA Therapeutics and Vaccines Revenue by Application (2018-2029)
• 7.3 Europe RNA Therapeutics and Vaccines Market Size by Country
  • 7.3.1 Europe RNA Therapeutics and Vaccines Revenue by Country: 2018 VS 2022 VS 2029
  • 7.3.2 Europe RNA Therapeutics and Vaccines Sales by Country (2018-2029)
  • 7.3.3 Europe RNA Therapeutics and Vaccines Revenue by Country (2018-2029)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China RNA Therapeutics and Vaccines Market Size
  • 8.1.1 China RNA Therapeutics and Vaccines Sales (2018-2029)
  • 8.1.2 China RNA Therapeutics and Vaccines Revenue (2018-2029)
• 8.2 China RNA Therapeutics and Vaccines Market Size by Application
  • 8.2.1 China RNA Therapeutics and Vaccines Sales by Application (2018-2029)
  • 8.2.2 China RNA Therapeutics and Vaccines Revenue by Application (2018-2029)

9 Asia (excluding China)

• 9.1 Asia RNA Therapeutics and Vaccines Market Size by Type
  • 9.1.1 Asia RNA Therapeutics and Vaccines Sales by Type (2018-2029)
  • 9.1.2 Asia RNA Therapeutics and Vaccines Revenue by Type (2018-2029)
• 9.2 Asia RNA Therapeutics and Vaccines Market Size by Application
  • 9.2.1 Asia RNA Therapeutics and Vaccines Sales by Application (2018-2029)
  • 9.2.2 Asia RNA Therapeutics and Vaccines Revenue by Application (2018-2029)
• 9.3 Asia RNA Therapeutics and Vaccines Sales by Region
  • 9.3.1 Asia RNA Therapeutics and Vaccines Revenue by Region: 2018 VS 2022 VS 2029
  • 9.3.2 Asia RNA Therapeutics and Vaccines Revenue by Region (2018-2029)
  • 9.3.3 Asia RNA Therapeutics and Vaccines Sales by Region (2018-2029)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Type (2018-2029)
  • 10.1.2 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Type (2018-2029)
• 10.2 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Application (2018-2029)
  • 10.2.2 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Application (2018-2029)
• 10.3 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Country
  • 10.3.1 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Country: 2018 VS 2022 VS 2029
  • 10.3.2 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Country (2018-2029)
  • 10.3.3 Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Country (2018-2029)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Company Profiles

• 11.1 Moderna
  • 11.1.1 Moderna Company Information
  • 11.1.2 Moderna Overview
  • 11.1.3 Moderna RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.1.4 Moderna RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Moderna Recent Developments
• 11.2 BioNTech (Pfizer)
  • 11.2.1 BioNTech (Pfizer) Company Information
  • 11.2.2 BioNTech (Pfizer) Overview
  • 11.2.3 BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.2.4 BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 BioNTech (Pfizer) Recent Developments
• 11.3 Sanofi
  • 11.3.1 Sanofi Company Information
  • 11.3.2 Sanofi Overview
  • 11.3.3 Sanofi RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.3.4 Sanofi RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Sanofi Recent Developments
• 11.4 Novartis
  • 11.4.1 Novartis Company Information
  • 11.4.2 Novartis Overview
  • 11.4.3 Novartis RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.4.4 Novartis RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Novartis Recent Developments
• 11.5 CureVac
  • 11.5.1 CureVac Company Information
  • 11.5.2 CureVac Overview
  • 11.5.3 CureVac RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.5.4 CureVac RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 CureVac Recent Developments
• 11.6 CSL
  • 11.6.1 CSL Company Information
  • 11.6.2 CSL Overview
  • 11.6.3 CSL RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.6.4 CSL RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 CSL Recent Developments
• 11.7 Arrowhead Pharmaceuticals
  • 11.7.1 Arrowhead Pharmaceuticals Company Information
  • 11.7.2 Arrowhead Pharmaceuticals Overview
  • 11.7.3 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.7.4 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Arrowhead Pharmaceuticals Recent Developments
• 11.8 Alnylam Pharmaceuticals
  • 11.8.1 Alnylam Pharmaceuticals Company Information
  • 11.8.2 Alnylam Pharmaceuticals Overview
  • 11.8.3 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.8.4 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 Alnylam Pharmaceuticals Recent Developments
• 11.9 GlaxoSmithKline (GSK)
  • 11.9.1 GlaxoSmithKline (GSK) Company Information
  • 11.9.2 GlaxoSmithKline (GSK) Overview
  • 11.9.3 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.9.4 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 GlaxoSmithKline (GSK) Recent Developments
• 11.10 Ionis Pharmaceuticals
  • 11.10.1 Ionis Pharmaceuticals Company Information
  • 11.10.2 Ionis Pharmaceuticals Overview
  • 11.10.3 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.10.4 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Ionis Pharmaceuticals Recent Developments
• 11.11 Regulus Therapeutics
  • 11.11.1 Regulus Therapeutics Company Information
  • 11.11.2 Regulus Therapeutics Overview
  • 11.11.3 Regulus Therapeutics RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.11.4 Regulus Therapeutics RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.11.5 Regulus Therapeutics Recent Developments
• 11.12 Roche
  • 11.12.1 Roche Company Information
  • 11.12.2 Roche Overview
  • 11.12.3 Roche RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.12.4 Roche RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.12.5 Roche Recent Developments
• 11.13 AstraZeneca
  • 11.13.1 AstraZeneca Company Information
  • 11.13.2 AstraZeneca Overview
  • 11.13.3 AstraZeneca RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.13.4 AstraZeneca RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.13.5 AstraZeneca Recent Developments
• 11.14 Sarepta Therapeutics
  • 11.14.1 Sarepta Therapeutics Company Information
  • 11.14.2 Sarepta Therapeutics Overview
  • 11.14.3 Sarepta Therapeutics RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.14.4 Sarepta Therapeutics RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.14.5 Sarepta Therapeutics Recent Developments
• 11.15 Orna Therapeutics
  • 11.15.1 Orna Therapeutics Company Information
  • 11.15.2 Orna Therapeutics Overview
  • 11.15.3 Orna Therapeutics RNA Therapeutics and Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.15.4 Orna Therapeutics RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.15.5 Orna Therapeutics Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 RNA Therapeutics and Vaccines Industry Chain Analysis
• 12.2 RNA Therapeutics and Vaccines Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 RNA Therapeutics and Vaccines Production Mode & Process
• 12.4 RNA Therapeutics and Vaccines Sales and Marketing
  • 12.4.1 RNA Therapeutics and Vaccines Sales Channels
  • 12.4.2 RNA Therapeutics and Vaccines Distributors
• 12.5 RNA Therapeutics and Vaccines Customers

13 Market Dynamics

• 13.1 RNA Therapeutics and Vaccines Industry Trends
• 13.2 RNA Therapeutics and Vaccines Market Drivers
• 13.3 RNA Therapeutics and Vaccines Market Challenges
• 13.4 RNA Therapeutics and Vaccines Market Restraints

14 Key Findings in The Global RNA Therapeutics and Vaccines Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

• Table 1. Global RNA Therapeutics and Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Table 2. Major Manufacturers of mRNA (messenger RNA) Therapeutics
• Table 3. Major Manufacturers of siRNA (small interfering RNA) Therapeutics
• Table 4. Major Manufacturers of Antisense Oligonucleotide Therapeutics
• Table 5. Global RNA Therapeutics and Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Table 6. Global RNA Therapeutics and Vaccines Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 7. Global RNA Therapeutics and Vaccines Revenue by Region (2018-2023) & (US$ Million)
• Table 8. Global RNA Therapeutics and Vaccines Revenue by Region (2024-2029) & (US$ Million)
• Table 9. Global RNA Therapeutics and Vaccines Revenue Market Share by Region (2018-2023)
• Table 10. Global RNA Therapeutics and Vaccines Revenue Market Share by Region (2024-2029)
• Table 11. Global RNA Therapeutics and Vaccines Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 12. Global RNA Therapeutics and Vaccines Sales by Region (2018-2023) & (K Units)
• Table 13. Global RNA Therapeutics and Vaccines Sales by Region (2024-2029) & (K Units)
• Table 14. Global RNA Therapeutics and Vaccines Sales Market Share by Region (2018-2023)
• Table 15. Global RNA Therapeutics and Vaccines Sales Market Share by Region (2024-2029)
• Table 16. Global RNA Therapeutics and Vaccines Sales by Manufacturers (2018-2023) & (K Units)
• Table 17. Global RNA Therapeutics and Vaccines Sales Share by Manufacturers (2018-2023)
• Table 18. Global RNA Therapeutics and Vaccines Revenue by Manufacturers (2018-2023) & (US$ Million)
• Table 19. Global RNA Therapeutics and Vaccines Revenue Share by Manufacturers (2018-2023)
• Table 20. Global Key Players of RNA Therapeutics and Vaccines, Industry Ranking, 2021 VS 2022 VS 2023
• Table 21. RNA Therapeutics and Vaccines Price by Manufacturers 2018-2023 (US$/Unit)
• Table 22. Global RNA Therapeutics and Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
• Table 23. Global RNA Therapeutics and Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Therapeutics and Vaccines as of 2022)
• Table 24. Global Key Manufacturers of RNA Therapeutics and Vaccines, Manufacturing Base Distribution and Headquarters
• Table 25. Global Key Manufacturers of RNA Therapeutics and Vaccines, Product Offered and Application
• Table 26. Global Key Manufacturers of RNA Therapeutics and Vaccines, Date of Enter into This Industry
• Table 27. Mergers & Acquisitions, Expansion Plans
• Table 28. Global RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
• Table 29. Global RNA Therapeutics and Vaccines Sales by Type (2024-2029) & (K Units)
• Table 30. Global RNA Therapeutics and Vaccines Sales Share by Type (2018-2023)
• Table 31. Global RNA Therapeutics and Vaccines Sales Share by Type (2024-2029)
• Table 32. Global RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & (US$ Million)
• Table 33. Global RNA Therapeutics and Vaccines Revenue by Type (2024-2029) & (US$ Million)
• Table 34. Global RNA Therapeutics and Vaccines Revenue Share by Type (2018-2023)
• Table 35. Global RNA Therapeutics and Vaccines Revenue Share by Type (2024-2029)
• Table 36. RNA Therapeutics and Vaccines Price by Type (2018-2023) & (US$/Unit)
• Table 37. Global RNA Therapeutics and Vaccines Price Forecast by Type (2024-2029) & (US$/Unit)
• Table 38. Global RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
• Table 39. Global RNA Therapeutics and Vaccines Sales by Application (2024-2029) & (K Units)
• Table 40. Global RNA Therapeutics and Vaccines Sales Share by Application (2018-2023)
• Table 41. Global RNA Therapeutics and Vaccines Sales Share by Application (2024-2029)
• Table 42. Global RNA Therapeutics and Vaccines Revenue by Application (2018-2023) & (US$ Million)
• Table 43. Global RNA Therapeutics and Vaccines Revenue by Application (2024-2029) & (US$ Million)
• Table 44. Global RNA Therapeutics and Vaccines Revenue Share by Application (2018-2023)
• Table 45. Global RNA Therapeutics and Vaccines Revenue Share by Application (2024-2029)
• Table 46. RNA Therapeutics and Vaccines Price by Application (2018-2023) & (US$/Unit)
• Table 47. Global RNA Therapeutics and Vaccines Price Forecast by Application (2024-2029) & (US$/Unit)
• Table 48. US & Canada RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
• Table 49. US & Canada RNA Therapeutics and Vaccines Sales by Type (2024-2029) & (K Units)
• Table 50. US & Canada RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & (US$ Million)
• Table 51. US & Canada RNA Therapeutics and Vaccines Revenue by Type (2024-2029) & (US$ Million)
• Table 52. US & Canada RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
• Table 53. US & Canada RNA Therapeutics and Vaccines Sales by Application (2024-2029) & (K Units)
• Table 54. US & Canada RNA Therapeutics and Vaccines Revenue by Application (2018-2023) & (US$ Million)
• Table 55. US & Canada RNA Therapeutics and Vaccines Revenue by Application (2024-2029) & (US$ Million)
• Table 56. US & Canada RNA Therapeutics and Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 57. US & Canada RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & (US$ Million)
• Table 58. US & Canada RNA Therapeutics and Vaccines Revenue by Country (2024-2029) & (US$ Million)
• Table 59. US & Canada RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
• Table 60. US & Canada RNA Therapeutics and Vaccines Sales by Country (2024-2029) & (K Units)
• Table 61. Europe RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
• Table 62. Europe RNA Therapeutics and Vaccines Sales by Type (2024-2029) & (K Units)
• Table 63. Europe RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & (US$ Million)
• Table 64. Europe RNA Therapeutics and Vaccines Revenue by Type (2024-2029) & (US$ Million)
• Table 65. Europe RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
• Table 66. Europe RNA Therapeutics and Vaccines Sales by Application (2024-2029) & (K Units)
• Table 67. Europe RNA Therapeutics and Vaccines Revenue by Application (2018-2023) & (US$ Million)
• Table 68. Europe RNA Therapeutics and Vaccines Revenue by Application (2024-2029) & (US$ Million)
• Table 69. Europe RNA Therapeutics and Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 70. Europe RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & (US$ Million)
• Table 71. Europe RNA Therapeutics and Vaccines Revenue by Country (2024-2029) & (US$ Million)
• Table 72. Europe RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
• Table 73. Europe RNA Therapeutics and Vaccines Sales by Country (2024-2029) & (K Units)
• Table 74. China RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
• Table 75. China RNA Therapeutics and Vaccines Sales by Type (2024-2029) & (K Units)
• Table 76. China RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & (US$ Million)
• Table 77. China RNA Therapeutics and Vaccines Revenue by Type (2024-2029) & (US$ Million)
• Table 78. China RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
• Table 79. China RNA Therapeutics and Vaccines Sales by Application (2024-2029) & (K Units)
• Table 80. China RNA Therapeutics and Vaccines Revenue by Application (2018-2023) & (US$ Million)
• Table 81. China RNA Therapeutics and Vaccines Revenue by Application (2024-2029) & (US$ Million)
• Table 82. Asia RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
• Table 83. Asia RNA Therapeutics and Vaccines Sales by Type (2024-2029) & (K Units)
• Table 84. Asia RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & (US$ Million)
• Table 85. Asia RNA Therapeutics and Vaccines Revenue by Type (2024-2029) & (US$ Million)
• Table 86. Asia RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
• Table 87. Asia RNA Therapeutics and Vaccines Sales by Application (2024-2029) & (K Units)
• Table 88. Asia RNA Therapeutics and Vaccines Revenue by Application (2018-2023) & (US$ Million)
• Table 89. Asia RNA Therapeutics and Vaccines Revenue by Application (2024-2029) & (US$ Million)
• Table 90. Asia RNA Therapeutics and Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 91. Asia RNA Therapeutics and Vaccines Revenue by Region (2018-2023) & (US$ Million)
• Table 92. Asia RNA Therapeutics and Vaccines Revenue by Region (2024-2029) & (US$ Million)
• Table 93. Asia RNA Therapeutics and Vaccines Sales by Region (2018-2023) & (K Units)
• Table 94. Asia RNA Therapeutics and Vaccines Sales by Region (2024-2029) & (K Units)
• Table 95. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
• Table 96. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Type (2024-2029) & (K Units)
• Table 97. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & (US$ Million)
• Table 98. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Type (2024-2029) & (US$ Million)
• Table 99. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
• Table 100. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Application (2024-2029) & (K Units)
• Table 101. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Application (2018-2023) & (US$ Million)
• Table 102. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Application (2024-2029) & (US$ Million)
• Table 103. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 104. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & (US$ Million)
• Table 105. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue by Country (2024-2029) & (US$ Million)
• Table 106. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
• Table 107. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales by Country (2024-2029) & (K Units)
• Table 108. Moderna Company Information
• Table 109. Moderna Description and Major Businesses
• Table 110. Moderna RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 111. Moderna RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 112. Moderna Recent Developments
• Table 113. BioNTech (Pfizer) Company Information
• Table 114. BioNTech (Pfizer) Description and Major Businesses
• Table 115. BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 116. BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 117. BioNTech (Pfizer) Recent Developments
• Table 118. Sanofi Company Information
• Table 119. Sanofi Description and Major Businesses
• Table 120. Sanofi RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 121. Sanofi RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 122. Sanofi Recent Developments
• Table 123. Novartis Company Information
• Table 124. Novartis Description and Major Businesses
• Table 125. Novartis RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 126. Novartis RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 127. Novartis Recent Developments
• Table 128. CureVac Company Information
• Table 129. CureVac Description and Major Businesses
• Table 130. CureVac RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 131. CureVac RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 132. CureVac Recent Developments
• Table 133. CSL Company Information
• Table 134. CSL Description and Major Businesses
• Table 135. CSL RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 136. CSL RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 137. CSL Recent Developments
• Table 138. Arrowhead Pharmaceuticals Company Information
• Table 139. Arrowhead Pharmaceuticals Description and Major Businesses
• Table 140. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 141. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 142. Arrowhead Pharmaceuticals Recent Developments
• Table 143. Alnylam Pharmaceuticals Company Information
• Table 144. Alnylam Pharmaceuticals Description and Major Businesses
• Table 145. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 146. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 147. Alnylam Pharmaceuticals Recent Developments
• Table 148. GlaxoSmithKline (GSK) Company Information
• Table 149. GlaxoSmithKline (GSK) Description and Major Businesses
• Table 150. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 151. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 152. GlaxoSmithKline (GSK) Recent Developments
• Table 153. Ionis Pharmaceuticals Company Information
• Table 154. Ionis Pharmaceuticals Description and Major Businesses
• Table 155. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 156. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 157. Ionis Pharmaceuticals Recent Developments
• Table 158. Regulus Therapeutics Company Information
• Table 159. Regulus Therapeutics Description and Major Businesses
• Table 160. Regulus Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 161. Regulus Therapeutics RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 162. Regulus Therapeutics Recent Developments
• Table 163. Roche Company Information
• Table 164. Roche Description and Major Businesses
• Table 165. Roche RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 166. Roche RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 167. Roche Recent Developments
• Table 168. AstraZeneca Company Information
• Table 169. AstraZeneca Description and Major Businesses
• Table 170. AstraZeneca RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 171. AstraZeneca RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 172. AstraZeneca Recent Developments
• Table 173. Sarepta Therapeutics Company Information
• Table 174. Sarepta Therapeutics Description and Major Businesses
• Table 175. Sarepta Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 176. Sarepta Therapeutics RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 177. Sarepta Therapeutics Recent Developments
• Table 178. Orna Therapeutics Company Information
• Table 179. Orna Therapeutics Description and Major Businesses
• Table 180. Orna Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 181. Orna Therapeutics RNA Therapeutics and Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
• Table 182. Orna Therapeutics Recent Developments
• Table 183. Key Raw Materials Lists
• Table 184. Raw Materials Key Suppliers Lists
• Table 185. RNA Therapeutics and Vaccines Distributors List
• Table 186. RNA Therapeutics and Vaccines Customers List
• Table 187. RNA Therapeutics and Vaccines Market Trends
• Table 188. RNA Therapeutics and Vaccines Market Drivers
• Table 189. RNA Therapeutics and Vaccines Market Challenges
• Table 190. RNA Therapeutics and Vaccines Market Restraints
• Table 191. Research Programs/Design for This Report
• Table 192. Key Data Information from Secondary Sources
• Table 193. Key Data Information from Primary Sources

List of Figures

• Figure 1. RNA Therapeutics and Vaccines Product Picture
• Figure 2. Global RNA Therapeutics and Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 3. Global RNA Therapeutics and Vaccines Market Share by Type in 2022 & 2029
• Figure 4. mRNA (messenger RNA) Therapeutics Product Picture
• Figure 5. siRNA (small interfering RNA) Therapeutics Product Picture
• Figure 6. Antisense Oligonucleotide Therapeutics Product Picture
• Figure 7. Global RNA Therapeutics and Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 8. Global RNA Therapeutics and Vaccines Market Share by Application in 2022 & 2029
• Figure 9. Hospitals
• Figure 10. Research Institutions
• Figure 11. RNA Therapeutics and Vaccines Report Years Considered
• Figure 12. Global RNA Therapeutics and Vaccines Revenue, (US$ Million), 2018 VS 2022 VS 2029
• Figure 13. Global RNA Therapeutics and Vaccines Revenue 2018-2029 (US$ Million)
• Figure 14. Global RNA Therapeutics and Vaccines Revenue Market Share by Region in Percentage: 2022 Versus 2029
• Figure 15. Global RNA Therapeutics and Vaccines Revenue Market Share by Region (2018-2029)
• Figure 16. Global RNA Therapeutics and Vaccines Sales 2018-2029 ((K Units)
• Figure 17. Global RNA Therapeutics and Vaccines Sales Market Share by Region (2018-2029)
• Figure 18. US & Canada RNA Therapeutics and Vaccines Sales YoY (2018-2029) & (K Units)
• Figure 19. US & Canada RNA Therapeutics and Vaccines Revenue YoY (2018-2029) & (US$ Million)
• Figure 20. Europe RNA Therapeutics and Vaccines Sales YoY (2018-2029) & (K Units)
• Figure 21. Europe RNA Therapeutics and Vaccines Revenue YoY (2018-2029) & (US$ Million)
• Figure 22. China RNA Therapeutics and Vaccines Sales YoY (2018-2029) & (K Units)
• Figure 23. China RNA Therapeutics and Vaccines Revenue YoY (2018-2029) & (US$ Million)
• Figure 24. Asia (excluding China) RNA Therapeutics and Vaccines Sales YoY (2018-2029) & (K Units)
• Figure 25. Asia (excluding China) RNA Therapeutics and Vaccines Revenue YoY (2018-2029) & (US$ Million)
• Figure 26. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales YoY (2018-2029) & (K Units)
• Figure 27. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue YoY (2018-2029) & (US$ Million)
• Figure 28. The RNA Therapeutics and Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
• Figure 29. The Top 5 and 10 Largest Manufacturers of RNA Therapeutics and Vaccines in the World: Market Share by RNA Therapeutics and Vaccines Revenue in 2022
• Figure 30. Global RNA Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
• Figure 31. Global RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• Figure 32. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• Figure 33. Global RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• Figure 34. Global RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• Figure 35. US & Canada RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• Figure 36. US & Canada RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• Figure 37. US & Canada RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• Figure 38. US & Canada RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• Figure 39. US & Canada RNA Therapeutics and Vaccines Revenue Share by Country (2018-2029)
• Figure 40. US & Canada RNA Therapeutics and Vaccines Sales Share by Country (2018-2029)
• Figure 41. U.S. RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 42. Canada RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 43. Europe RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• Figure 44. Europe RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• Figure 45. Europe RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• Figure 46. Europe RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• Figure 47. Europe RNA Therapeutics and Vaccines Revenue Share by Country (2018-2029)
• Figure 48. Europe RNA Therapeutics and Vaccines Sales Share by Country (2018-2029)
• Figure 49. Germany RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 50. France RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 51. U.K. RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 52. Italy RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 53. Russia RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 54. China RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• Figure 55. China RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• Figure 56. China RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• Figure 57. China RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• Figure 58. Asia RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• Figure 59. Asia RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• Figure 60. Asia RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• Figure 61. Asia RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• Figure 62. Asia RNA Therapeutics and Vaccines Revenue Share by Region (2018-2029)
• Figure 63. Asia RNA Therapeutics and Vaccines Sales Share by Region (2018-2029)
• Figure 64. Japan RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 65. South Korea RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 66. China Taiwan RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 67. Southeast Asia RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 68. India RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 69. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2029)
• Figure 70. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2029)
• Figure 71. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2029)
• Figure 72. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2029)
• Figure 73. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Revenue Share by Country (2018-2029)
• Figure 74. Middle East, Africa and Latin America RNA Therapeutics and Vaccines Sales Share by Country (2018-2029)
• Figure 75. Brazil RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 76. Mexico RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 77. Turkey RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 78. Israel RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 79. GCC Countries RNA Therapeutics and Vaccines Revenue (2018-2029) & (US$ Million)
• Figure 80. RNA Therapeutics and Vaccines Value Chain
• Figure 81. RNA Therapeutics and Vaccines Production Process
• Figure 82. Channels of Distribution
• Figure 83. Distributors Profiles
• Figure 84. Bottom-up and Top-down Approaches for This Report
• Figure 85. Data Triangulation
• Figure 86. Key Executives Interviewed